Team:ATOMS-Turkiye
From 2014.igem.org
Sayinorhan (Talk | contribs) |
|||
(9 intermediate revisions not shown) | |||
Line 46: | Line 46: | ||
- | + | ||
- | + | ||
- | + | ||
}); | }); | ||
Line 63: | Line 61: | ||
<li><a href="https://2014.igem.org/Team:ATOMS-Turkiye/Data"><img src="https://static.igem.org/mediawiki/2014/9/94/ATOMS-Turkiye_right_2.png" /></a></li> | <li><a href="https://2014.igem.org/Team:ATOMS-Turkiye/Data"><img src="https://static.igem.org/mediawiki/2014/9/94/ATOMS-Turkiye_right_2.png" /></a></li> | ||
<li><a href="https://2014.igem.org/Team:ATOMS-Turkiye/Interlab-Study"><img src="https://static.igem.org/mediawiki/2014/5/58/ATOMS-Turkiye_right_3.png" /></a></li> | <li><a href="https://2014.igem.org/Team:ATOMS-Turkiye/Interlab-Study"><img src="https://static.igem.org/mediawiki/2014/5/58/ATOMS-Turkiye_right_3.png" /></a></li> | ||
- | <li><a href="https://2014.igem.org/Team:ATOMS-Turkiye/ | + | <li><a href="https://2014.igem.org/Team:ATOMS-Turkiye/Practices-Approach"><img src="https://static.igem.org/mediawiki/2014/2/23/ATOMS-Turkiye_right_4.png" /></a></li> |
</ul> | </ul> | ||
Line 69: | Line 67: | ||
<ul class="bxslider" style="margin: 0;"> | <ul class="bxslider" style="margin: 0;"> | ||
- | <li><img src="https://static.igem.org/mediawiki/2014/thumb/3/33/ATOMS-main-1.jpg/800px-ATOMS-main-1.jpg" title= "Our | + | <li><img src="https://static.igem.org/mediawiki/2014/thumb/3/33/ATOMS-main-1.jpg/800px-ATOMS-main-1.jpg" title= "Our blood vessels consist of three layers named as the endothelium, muscular and outer layer which allow oxygen and nutrient rich blood to flow through and diffuse into tissue cells. "></li> |
- | <li><img src="https://static.igem.org/mediawiki/2014/thumb/6/6c/ATOMS-main-2.jpg/800px-ATOMS-main-2.jpg" title= "In some cases such as excessive body weight or diabetes, | + | <li><img src="https://static.igem.org/mediawiki/2014/thumb/6/6c/ATOMS-main-2.jpg/800px-ATOMS-main-2.jpg" title= "In some cases such as excessive body weight or diabetes, accumulation of fat may occur on the surface of endothelium leading to the eventual formation of plaques."></li> |
- | <li><img src="https://static.igem.org/mediawiki/2014/thumb/8/84/ATOMS-main-3.jpg/800px-ATOMS-main-3.jpg" title= " | + | <li><img src="https://static.igem.org/mediawiki/2014/thumb/8/84/ATOMS-main-3.jpg/800px-ATOMS-main-3.jpg" title= "Plaques may continue to increase in size and narrow the lumens of our vessels, decreasing and limiting the blood flow to tissues and resulting in the escalation of surface tension."></li> |
- | <li><img src="https://static.igem.org/mediawiki/2014/thumb/2/2a/ATOMS-main-4.jpg/800px-ATOMS-main-4.jpg" title= " | + | <li><img src="https://static.igem.org/mediawiki/2014/thumb/2/2a/ATOMS-main-4.jpg/800px-ATOMS-main-4.jpg" title= "The increase of tension in the lumen is highly likely to rupture the plaques and cause the eventual formation of the blood coagulation cascade."></li> |
- | <li><img src="https://static.igem.org/mediawiki/2014/thumb/d/d7/ATOMS-main-5.jpg/800px-ATOMS-main-5.jpg" title= " | + | <li><img src="https://static.igem.org/mediawiki/2014/thumb/d/d7/ATOMS-main-5.jpg/800px-ATOMS-main-5.jpg" title= "The process of coagulation results in the superfluous formation of a clot which has a tendency to grow larger. "></li> |
- | <li><img src="https://static.igem.org/mediawiki/2014/thumb/1/1b/ATOMS-main-6.jpg/800px-ATOMS-main-6.jpg" title= " | + | <li><img src="https://static.igem.org/mediawiki/2014/thumb/1/1b/ATOMS-main-6.jpg/800px-ATOMS-main-6.jpg" title= "If this is the case, the clot inevitably blocks the path of the bloodstream hence distrupting the oxygen and nutrient supply to tissue cells."></li> |
- | <li><img src="https://static.igem.org/mediawiki/2014/thumb/1/15/ATOMS-main-7.jpg/800px-ATOMS-main-7.jpg" title= "As blood contains oxygen and | + | <li><img src="https://static.igem.org/mediawiki/2014/thumb/1/15/ATOMS-main-7.jpg/800px-ATOMS-main-7.jpg" title= "As the blood contains oxygen and nutrients which are essential for energy production and survival of cells, tissues become oxygen and nutrient depleted which we term as Hypoxia."></li> |
- | <li><img src="https://static.igem.org/mediawiki/2014/thumb/c/ca/ATOMS-main-8.jpg/800px-ATOMS-main-8.jpg" title= " | + | <li><img src="https://static.igem.org/mediawiki/2014/thumb/c/ca/ATOMS-main-8.jpg/800px-ATOMS-main-8.jpg" title= "Our project poses the sensing of hypoxia in early stages by using our engineered endothelial cells and activating the pathway to solve this leading cause of death worldwide."></li> |
- | <li><img src="https://static.igem.org/mediawiki/2014/thumb/f/fe/ATOMS-main-8a.jpg/800px-ATOMS-main-8a.jpg" title= " | + | <li><img src="https://static.igem.org/mediawiki/2014/thumb/f/fe/ATOMS-main-8a.jpg/800px-ATOMS-main-8a.jpg" title= "However as we dissolve the clot, blood supply is enabled which has a high possibility of causing an oxidative burst. We also eliminate the potential occurence of this via our engineered cells."></li> |
- | <li><img src="https://static.igem.org/mediawiki/2014/thumb/a/aa/ATOMS-main-9.jpg/800px-ATOMS-main-9.jpg" title= " | + | <li><img src="https://static.igem.org/mediawiki/2014/thumb/a/aa/ATOMS-main-9.jpg/800px-ATOMS-main-9.jpg" title= "With our novel sensing and protective systems, evaluation of clinical presence will no longer be required to treat hypoxic conditions."></li> |
- | <li><img src="https://static.igem.org/mediawiki/2014/thumb/7/78/ATOMS-main-10.jpg/800px-ATOMS-main-10.jpg" title= " | + | |
+ | <li><img src="https://static.igem.org/mediawiki/2014/thumb/7/78/ATOMS-main-10.jpg/800px-ATOMS-main-10.jpg" title= "Hence, our unique design of mechanism will now be a remedy to the leading cause of deaths worldwide. "></li> | ||
</ul> | </ul> | ||
Line 95: | Line 94: | ||
<ul> | <ul> | ||
<li class="one"> | <li class="one"> | ||
- | <div><a href="https://2014.igem.org/Team:ATOMS-Turkiye/Modeling" class="tit">Modeling</a><a href="https://2014.igem.org/Team:ATOMS-Turkiye/Modeling" class="lnk"><span><strong>This year | + | <div><a href="https://2014.igem.org/Team:ATOMS-Turkiye/Modeling" class="tit">Modeling</a><a href="https://2014.igem.org/Team:ATOMS-Turkiye/Modeling" class="lnk"><span><strong style="font-size:15px;margin-left: 0px;margin-right: 15px;">This year we carried out mathematical modeling to comprehend how our promoter system would react against hypoxia in order to treat heart related problems. In addition to this, we have also modeled our safety experiment to show its successful outcome mathematically. For more information, click here...</strong></span></a> |
<img src="https://static.igem.org/mediawiki/2014/thumb/6/6f/ATOMS-main-modeling.png/685px-ATOMS-main-modeling.png" alt="This year, we have carried out ..." width="210" height="220"><b>This year, we have carried out ....</b> | <img src="https://static.igem.org/mediawiki/2014/thumb/6/6f/ATOMS-main-modeling.png/685px-ATOMS-main-modeling.png" alt="This year, we have carried out ..." width="210" height="220"><b>This year, we have carried out ....</b> |
Latest revision as of 03:55, 18 October 2014
Project Abstract
The condition which results in tissue death due to the poor conveyance of oxygen and other products vital for tissue cells and organs is described as tissue hypoxia or ischemia. Currently, ischemia and other related conditions such as heart attacks and strokes take the lead for being the number one cause of death worldwide. Moreover, the current treatment of ischemic attacks can intensify the damage in the tissue caused by hypoxia which is known as oxidative stress. This is due to the high oxygen concentration of the restored blood supply. Without a doubt, we need to view the bigger picture of the condition in order to solve this problem. In our project, we desire to build two different devices which work synergistically and fix these these two distinct situations, hypoxia and oxidative stress. Hence, we have decided to use "hypoxia inducible systems" and "reactive oxygen species (ROS) sensitive gene fragments". These two receptors will regulate the release of clot dissolving factors and antioxidant peptides synthesized by our engineered vessel cells. Through attaining encouraging in-vitro results, we aim to pave the way of this promising system into a lifesaving remedy.
-
ModelingThis year we carried out mathematical modeling to comprehend how our promoter system would react against hypoxia in order to treat heart related problems. In addition to this, we have also modeled our safety experiment to show its successful outcome mathematically. For more information, click here... This year, we have carried out ....
-
BioBricksOur team proposes seven new eukaryotic cell parts to the Registry consisting of three promoters and four different enzymes with various capabilities. To get detailed information, proceed here. Our team proposes seven new eukaryotic cell parts ...